Xcout Intel
Laguna Pharmaceuticals, Inc.
Laguna Pharmaceuticals is a biotechnology company developing precision microbial immunotherapy platforms to treat various cancers, including high-risk leukemias and soft-tissue sarcomas. The company utilizes engineered, highly attenuated microbial vectors to activate and expand innate T cells directly within the body, aiming to overcome immune evasion by tumors.
Subscribe to see Laguna Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Laguna Pharmaceuticals, Inc. at a glance
Laguna Pharmaceuticals, Inc. is a biotechnology company headquartered in United States. It has raised at least $34.5M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $30M in February 2015. Xcout tracks 2 named people at Laguna Pharmaceuticals, Inc., including Jonathan Kotula (CEO and Co-Founder).
Laguna Pharmaceuticals, Inc. leadership
- Jonathan KotulaCEO and Co-Founder
- Russell CarringtonCOO and Co-Founder
Laguna Pharmaceuticals, Inc. funding rounds
At least $34.5M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series B | $30M | — | |
| SEC Form D filing | $4.5M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Laguna Pharmaceuticals, Inc. competitors
A few of Laguna Pharmaceuticals, Inc.'s closest competitors — see the full list of competitors and alternatives →
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
Elicera Therapeutics is a clinical-stage immuno-oncology company that develops genetically engineered cell and gene therapies, including CAR T-cell therapies and oncolytic viruses, to treat various types of cancer. The company utilizes its proprietary iTANK technology platform to enhance the immune system's ability to target and attack solid tumors.
Altamira Therapeutics Ltd. is a biotechnology company developing RNA-based cancer therapies using its proprietary xPhore nanoparticle delivery technology. Its lead candidate, ATX-402, is designed to systemically deliver therapeutic mRNA to reprogram the tumor microenvironment and improve cancer immunotherapy outcomes for patients.
Core Biomedicine is a preclinical-stage biotechnology and pharmaceutical manufacturing company pioneering lineage-based precision oncology therapeutics.
ArsenalBio is a biotechnology company developing programmable cell therapies, particularly engineered T-cell therapies, for cancer treatment. It serves biopharmaceutical and healthcare markets by using synthetic biology and genomic engineering to create more effective, controllable immune-cell medicines.
Get Laguna Pharmaceuticals, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Laguna Pharmaceuticals, Inc. in Xcout Intel
- 2 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access